Madrigal Pharmaceuticals, Inc. engages in the development and commercialization of therapeutics for metabolic dysfunction-associated steatohepatitis. The company was founded by Rebecca A. Taub, Frederick Bernard Craves, and Edward Chiang on March 10, 2000 and is headquartered in West Conshohocken, PA.
Fundamentals
Mkt Cap
$10.8B
Volume
-
52W High
$615.00
52W Low
$393.61
PE Ratio
-35.54
Avg. Volume
225,384.34
EPS (Annual)
-$12.85
P/B
20.19
Rev/Employee
$1,047,434.97
Earnings
Nov 03
51
Neutral Sentiment
How do you feel about MDGL?
BioEu
$MDGL ✅ These are just forecasts; I believe we will have to wait until the day the quarterly results are released, with the shares already trading in the 500–510 range.
5
BioEu
$MDGL ✅ After a long absence from Madrigal, I’m back. This pullback offers an excellent entry point, with the aim of capitalizing on the upcoming quarterly results—it’s a fantastic company, with solid revenue growth and no competitors at the moment. GO MADRIGAL!
6
timfris
$MDGL the only good news is that I’ve seen this happen before earnings only to skyrocket afterwords.
Also, the drag on the SP would raise chances of a deal, IMO, as it would show a higher premium at buyout.
1
1
sarkar20
$MDGL
Most of the times this kind if manipulation (without any news) is seen before BO!! Hope this is the case for MDGL too, BO soon?
1
2
forprofit12
$MDGL ER has mostly been a drag recently. Hopefully this time it would change. Have they announced ER as yet?
3
Wallst45
$MDGL CITI INITIATES MADRIGAL PHARMACEUTICALS COVERAGE WITH BUY RATING AND $725 PT
The firm believes the company's Rezdiffra is being underappreciated at current share levels. The launch has exceeded expectations and "blockbuster status is imminent"
4
NON_FICTION_1
$MDGL 👈i wont post much here either. Less then 3 years this biotech gets buyout. Dont at me later. Another just load and hold. No trades.
3
balzofsteel
$MDGL Citigroup Initiates Coverage On Madrigal Pharmaceuticals with Buy Rating, Announces Price Target of $725
Benzinga 2026-09-23T11:04:00-04:00
Citigroup analyst Eric Joseph initiates coverage on Madrigal Pharmaceuticals (MDGL.NaE) with a Buy rating and announces Price Target of $725
3
Live2ride
$MDGL This is starting to feel like a last ditch effort to get retail traders shares before they let it rip into EOY. I think M&A picks up before Dec 31st.
2
Live2ride
$MDGL Back to buy zone for me. Not sure if a swing or core. Market may decide that for me.
2
forprofit12
$MDGL and? Price is still pathetic. Regret adding this. The lost opportunity cost on this one is huge.
2
forprofit12
$MDGL something not good. 2.7x volume and red is not a good sign. It is also trading at recent lows.
1
Whiskeyunderthebed
$MDGL Has nothing to do with it- sector rotation and money are leaving health care sector-
1
sarkar20
$MDGL
I guess there is no BO and it seems not good things in future the way stock price is moving these days!!